POSTER #1.364
Depression Symptom Experience Among Patients with Epilepsy Reporting a Diagnosis of Focal Seizures (FS): A Patient-Reported Outcomes Study
Joanne Wagner, Bhagyashree Oak, Brittany Smith, Amond Athavale, Alvin Ong, Cynthia Harden
Healthcare providers
Science-driven innovation for better patient outcomes
At Xenon, we are focused on developing medicines that modulate ion channels to address neurological and psychiatric disorders. Our lead investigational candidate, azetukalner, is a Kv7 potassium channel opener in late-stage clinical development for multiple epilepsy indications (focal and generalized seizures) and depression (major depressive disorder and bipolar depression). Our early-stage pipeline leverages this same ion channel expertise to target chronic and acute pain and severe genetically defined epilepsies, like Dravet syndrome.
AES Annual Meeting
December 5–9, 2025
The AES Annual Meeting brings together healthcare providers, scientists, advocates, industry, and other professionals dedicated to better outcomes for people with epilepsy.
Exhibit Hall
Saturday, December 6, 2025 | 12 PM ET – Monday, December 8, 2025 | 2 PM ET
Booths #133 and #233
Satellite Symposium in Partnership with Epilepsy Foundation of America (EFA)
A conversation focused on "Exploring Depression and Anxiety in Epilepsy: A Practical Dialogue with Patients and Providers"
Saturday, December 6, 2025
6 PM – 9 PM ET
Room B213
Scientific Exhibit
Sunday, December 7, 2025
2 PM – 5 PM ET
Room B305
AES 2025 Poster Presentation Information
Saturday, December 6, 2025
12 PM – 2 PM ET
Exhibit Hall B2, Poster Session 1
POSTER #1.365
Impact of Depression on Outcomes and Treatment Patterns in Patients with Newly Diagnosed Epilepsy: A Retrospective Claims Analysis
Samuel Terman, Alving Ong, Tigwa Davis, Anthony Yu, Yecheng Huang, CJ Park, Dan Thorton
POSTER #1.377
Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice
Danielle Becker, Jacqueline A. French, Jenny Qian, Lee Gervitz
Sunday, December 7, 2025
12 PM – 2 PM ET
Exhibit Hall B2, Poster Session 2
POSTER #2.325
Multivariable Models Reporting Increased Economic and Humanistic Burden Among Patients With Epilepsy Reporting Focal Seizures (FS) Experiencing Moderate to Severe Depression Symptoms
Alvin Ong, Joanne Wagner, Bhagyashree Oak, Brittany Smith, Amond Athavale, Cynthia Harden
POSTER #2.367
Clinical Practice and Patient Burden Associated with Anti-Seizure Medication Titration: A Thematic Analysis
John Stern, Danielle Becker, Steve Chung, Michael Macken, David King-Stephen, Andrew Zillgitt, Mohamad Koubeissi
Monday, December 8, 2025
12 PM – 1:45 PM ET
Exhibit Hall B2, Poster Session 3
POSTER #3.181
Selective Potentiation of Nav1.1 Channels in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP and Increases Long Term Potentiation
Samuel Goodchild, Kristen Buford, Celine Dube, Samrat Thouta, Arjun Mahadevan, Matt Waldbrook, Alison Cutts, Megan Soriano, Maja Filipovic, Vishaal Rajani, Emily Hurley, Verner Lofstrand, Helen Clement, Davie Kim, Steven Wesolowski, James Empfield, JP Johnson Jr.
POSTER #3.356
Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent Kv7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥42-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension
Jacqueline French, Roger Porter, Emilio Perucca, Martin Brodie, Cynthia Harden, Jenny Qian, Constanza Luzon Rosenblut, Christopher Kenney, Gregory N. Beatch
Featured publications
Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial
JAMA NeurologyEfficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: <span>A Phase 2b Randomized Clinical Trial</span>Interim Analysis of the Long-term Efficacy and Safety of Azetukalner in an Ongoing Open-label Extension Study Following a Phase 2b Clinical Trial (X-TOLE) in Adults with Focal Epilepsy
Epilepsia OpenInterim Analysis of the Long-term Efficacy and Safety of Azetukalner in an Ongoing Open-label Extension Study Following a Phase 2b Clinical Trial (X-TOLE) in Adults with Focal EpilepsyAzetukalner, a Novel Kv7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial
JAMA Network OpenAzetukalner, a Novel Kv7 Potassium Channel Opener, in Adults With Major Depressive Disorder: <span>A Randomized Clinical Trial</span>
Meet with your MSL
To meet a Medical Science Liaison (MSL) in your region, please fill out this form.
Spotlight on epilepsy
Hear from leading voices in the epilepsy field as they discuss current treatments and opportunities to improve patient care
Video Name
Clinical trials
We are actively enrolling patients in late-stage clinical trials across a spectrum of challenging neurological and psychiatric disorders, building upon promising Phase 2 data. This pivotal studies include:
Read our brochure to learn more about our Phase 3 clinical trials in epilepsy
Expanded access
Xenon Pharmaceuticals is committed to developing innovative, safe, and effective therapeutics to improve the lives of patients with neurological disorders, and we recognize the value of collaborating with patients, families, advocacy organizations, physicians and other healthcare professionals, researchers, and regulatory authorities to accomplish this goal.
We understand that patients, families, and physicians may be interested in accessing Xenon’s investigational drugs prior to regulatory approval through an expanded access program (sometimes referred to as “compassionate use program”). Expanded access programs allow patients with serious or immediately life‑threatening diseases, who have exhausted all other treatment options, to access an investigational drug outside of a clinical trial and prior to regulatory approval.
Xenon does not currently have an expanded access program that makes our investigational drugs available to patients other than by participating in one of our clinical trials. Clinical trials are controlled studies in humans designed to establish whether an investigational drug is safe and effective. Xenon believes clinical trials are the most appropriate way to efficiently collect all data necessary to seek regulatory approvals. At this time, Xenon does not have sufficient information about the potential risks and benefits of our investigational drugs to ensure that patient access outside the regulated clinical trial process does not delay or compromise our clinical trials and, ultimately, broad availability to the entire patient community.
Physicians, patients, and caregivers interested in learning more about Xenon’s ongoing clinical trials can find additional information at ClinicalTrials.gov.
Xenon may revise this policy at any time. If you have additional questions, please contact us at info@xenon-pharma.com.